scholarly journals A model of free-living gait: A factor analysis in Parkinson’s disease

2017 ◽  
Vol 52 ◽  
pp. 68-71 ◽  
Author(s):  
Rosie Morris ◽  
Aodhán Hickey ◽  
Silvia Del Din ◽  
Alan Godfrey ◽  
Sue Lord ◽  
...  
2006 ◽  
Vol 6 (1) ◽  
Author(s):  
Pieter M Kroonenberg ◽  
Frans J Oort ◽  
Glenn T Stebbins ◽  
Sue E Leurgans ◽  
Esther Cubo ◽  
...  

2021 ◽  
pp. 1-12
Author(s):  
Anna Sauerbier ◽  
Pia Bachon ◽  
Leire Ambrosio ◽  
Philipp A. Loehrer ◽  
Alexandra Rizos ◽  
...  

Background: The satisfaction with life and, in particular, with treatment in Parkinson’s disease (PD) is understudied. Objective: To explore a new 7-item rating tool assessing satisfaction with life and treatment (SLTS-7) in PD. Methods: In this cross-sectional, multi-center study, including patients screened for advanced therapies, psychometric characteristics of the SLTS-7 were analyzed. An exploratory factor analysis identified the underlying factorial structure of the SLTS-7. Results: 117 patients were included, and the data quality of the SLTS-7 was excellent (computable data 100%), and acceptability measures satisfied standard criteria. Besides the global assessment (item 1), the exploratory factor analysis produced item 2 (physical satisfaction) as an independent item and two factors among the remaining items: items 3–5 (psycho-social satisfaction), and items 6 and 7 (treatment satisfaction). Cronbach’s alpha was 0.89, indicative of high internal consistency. The SLTS-7 total score correlated moderately with motor symptoms and weakly with non-motor symptoms total scores. SLTS-7 showed the highest correlations with the European Quality of Life with 5 items (EQ-5D) visual analog scale (0.43–0.58, p <  0.01), indicating a moderate convergent validity. The SLTS-7 significantly increased with higher non-motor symptoms burden levels (p = 0.002). Conclusion: Life satisfaction in PD covers three specific aspects, namely physical, psycho-social, and treatment satisfaction. The new SLTS-7 is a valid, reliable, and easy-to-use tool to assess satisfaction with life and treatment in patients with PD screened for advanced therapies. Longitudinal studies analyzing the effect of advanced PD treatment on life and treatment satisfaction are warranted.


2019 ◽  
Vol 6 (5) ◽  
pp. 379-386 ◽  
Author(s):  
Francesca V. Lopez ◽  
Graham M.L. Eglit ◽  
Dawn M. Schiehser ◽  
Eva Pirogovsky‐Turk ◽  
Irene Litvan ◽  
...  

2014 ◽  
Vol 22 (4) ◽  
pp. 550-556 ◽  
Author(s):  
Martin Benka Wallén ◽  
Ing-Mari Dohrn ◽  
Agneta Ståhle ◽  
Erika Franzén ◽  
Maria Hagströmer

Aim:To compare self-reported pedometer steps with accelerometer steps under free-living conditions in individuals with Parkinson’s disease (PD) or osteoporosis (OP).Methods:Seventy-three individuals with PD and 71 individuals with OP wore a pedometer (Yamax LS2000) and an accelerometer (ActiGraph GT1M/GT3X+) simultaneously for one week.Results:Fifty-one individuals with PD (72.6 ± 5.3 years) and 61 with OP (75.6 ± 5.3 years) provided simultaneously recorded data for 3–7 consecutive days. Pedometer steps were significantly lower than accelerometer steps in the PD group (p = .002) but not in the OP group (p = .956). Bland-Altman plots demonstrated wide limits of agreement between the instruments in both PD (range = 6,911 steps) and OP (range = 6,794 steps).Conclusion:These results suggest that the ActiGraph GT1M/GT3X+ should be preferred over the Yamax LS2000 for the assessment of steps in both research and clinical evaluations, particularly in individuals with PD or altered gait.


Sign in / Sign up

Export Citation Format

Share Document